A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.
Also called NCT07570940
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 450 participants
- Sponsor
- Registry
-
NCT07570940
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07570940. Randomized; double masking; primary purpose treatment. Start 2026-09-14 (anticipated); primary completion 2030-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
- Condition
- Coronary Artery Disease
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Liposomal bupivacaine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Mayo Clinic
Record details
- Record id
cardio:ct-nct07570940- Content hash
8d881211e9267de9fd096088b234aa80234dc34e6b45199336023fa94830ae92